GLP-1 injection pen patents can automatically delay generic competition by also claiming the active ingredient.

Manufacturing Chemist’s Emily Letton reports that more than half of the patents listed on GLP-1 drugs cover delivery devices such as pens and dose counters. A listed patent appears in the Orange Book, the FDA’s register of patents that every generic applicant must address. Pinsent Masons data shows GLP-1 patent applications rose 146% in five years, to 936 in the year to March 2026.

Hatch-Waxman and the Teva v. Amneal Standard

Semaglutide is a 31-amino-acid peptide, short enough to be regulated as a drug rather than a biologic. U.S. generic approval therefore proceeds under the Hatch-Waxman Act. A timely suit on a listed patent automatically delays FDA approval of a generic for up to 30 months.

In Teva v. Amneal (2024), the Federal Circuit held that a patent must claim at least the active ingredient to be listed. A patent claiming the pen combined with the drug can meet that test. A patent claiming only the pen can still be enforced in court, but does not qualify for the automatic delay.

Formulation Patents and Global Exclusivity Timelines

GLP-1 pills rely on different patents. Rybelsus, the semaglutide tablet, relies on listed formulation patents that pair semaglutide with an absorption enhancer and expire as late as 2033. Lilly’s Foundayo, approved in April 2026, is a different molecule with separate patents.

Generic semaglutide is poised to enter Canada, India, China, and Brazil this year. The U.S. semaglutide compound patent runs to December 2031, and tirzepatide’s compound patent runs to 2036.

AI Drug Discovery and Enablement Challenges

AI is also reshaping GLP-1 drug discovery. MindRank’s MDR-001, an oral GLP-1 drug developed on a generative AI platform, is in Phase III in China. Only humans can be inventors in the U.S. (see Teva v. Amneal), and USPTO guidance treats AI as a tool. As a prior post in this series explained, the open question is which humans conceived the claimed invention.

AI platforms can generate thousands of therapeutic candidates, inviting broad claims to molecule families defined by receptor activity. Under Amgen v. Sanofi (2023), the Supreme Court requires a patent to teach how to make and use the full scope of such a claim, and a roadmap for trial-and-error screening typically does not suffice.

Takeaways for Innovators and Generics

  • Device-only Orange Book listings invite challenges from generic makers and Federal Trade Commission scrutiny.
  • Claims to AI-derived candidates are more defensible when tied to compounds made and tested, with records of who selected them.
  • Generic entrants must assess patent risk country by country.

The compound patent sets the earliest date generic semaglutide can enter each market. Later pen and formulation patents, and the precision of claims on AI-derived successors, will help determine the scope of remaining exclusivity.

Sources

  1. 1. Emily Letton, GLP-1 patent applications surge 146% in five years as semaglutide cliff drives evergreening and biosimilar race, Manufacturing Chemist (Sept. 29, 2026): https://manufacturingchemist.com/glp-1-patent-applications-surge-semaglutide-cliff-biosimilar
  2. 2. Pinsent Masons, Patent data reveals push to use weight-loss drugs for treating cancer, Out-Law (Oct. 9, 2026): https://www.pinsentmasons.com/out-law/news/patent-data-weight-loss-drugs-cancer
  3. 3. Teva Branded Pharm. Prods. R&D, Inc. v. Amneal Pharms. of N.Y., LLC, No. 24-1936 (Fed. Cir. Dec. 20, 2024)
  4. 4. FTC, Letter to Novo Nordisk Inc. disputing 17 Ozempic Orange Book listings (Apr. 30, 2024): https://www.ftc.gov/system/files/ftc_gov/pdf/novo-nordisk-ozempic-saxenda-victoza-_4302024.pdf
  5. 5. Rybelsus Orange Book formulation listings, e.g., U.S. Patent Nos. 9,278,123 (Dec. 16, 2031), 11,033,499 (June 19, 2033), and 11,759,501 (Mar. 15, 2033)
  6. 6. FDA approval of Foundayo (orforglipron), Apr. 1, 2026, reported by ABC News: https://abc7news.com/post/fda-grants-speedy-approval-eli-lillys-weight-loss-glp-1-pill-foundayo-obesity/18823509/
  7. U.S. Patent No. 8,129,343 (semaglutide compound; Orange Book expiry Dec. 5, 2031, with term extension); Novo Nordisk v. Mylan, No. 1:23-cv-00101 (D. Del.) (proposed judgment, Mar. 2026)
  8. U.S. Patent No. 9,474,780 (tirzepatide compound; Orange Book expiry May 13, 2036; later-listed patents extend to 2041)
  9. Thaler v. Vidal, 43 F.4th 1207 (Fed. Cir. 2022)
  10. Revised Inventorship Guidance for AI-Assisted Inventions, 90 Fed. Reg. 54636 (Nov. 28, 2025)
  11. Amgen Inc. v. Sanofi, 598 U.S. 594 (2023)
  12. MindRank Series B and MDR-001 Phase III, AllSci (July 10, 2026): https://allsci.com/news/funding/venture-financing/mindranks-usd-52m-series-b-advances-ai-designed-glp-1-into-pivotal-phase-iii-obesity-trial/
  13. Crediting an AI With a Discovery Invites Challenges About Which Humans Conceived It, Pioneering IP (Sept. 11, 2026): https://blog.patrickiplaw.com/crediting-an-ai-with-a-discovery-invites-challenges-about-which-humans-conceived-it